KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trial.

Kazutaka Sunami, Hiroshi Handa, Michiko Ichii, Takayuki Ikezoe, Kazuhito Suzuki, Yusuke Yamaguchi, Taeko Yonekawa, Akira Endo, Hirofumi Nakano, Eric Lewis, Ianire Garrobo Calleja, Elisabet Manasanch, Shigeki Ito, Hitomi Kato

Int J Hematol 123(5) 686-695

PMID41493718
PMCIDPMC13171770
DOI10.1007/s12185-025-04150-6
发表日期2026-01-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The phase 3 DREAMM-8 (NCT04484623) trial assessed belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs bortezomib + Pd (PVd) in lenalidomide-exposed patients with relapsed/refractory multiple myeloma (RRMM) and ≥ 1 prior therapy. Here, we present findings from Japanese patients (data cutoff: 27-May-24). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), duration of response (DoR), and safety. Overall, 21 patients were randomized 1:1 to BPd (N = 10) and PVd (N = 11). Median follow-up was 13.8 months (range 0.23-26.71). For BPd vs PVd, median PFS was not reached (NR; 95% CI 0.2-NR) vs 14.8 months (95% CI 1.9-NR; HR 0.53; 95% CI 0.1-2.8); ORR was 90% (9/10) vs 73% (8/11), including very good partial response or better in 70% (7/10) vs 36% (4/11); median DoR was NR vs 17.5 months. The safety profile was consistent with the global cohort. Ocular adverse events were more common with BPd vs PVd (90% [9/10] vs 9% [1/11]) and a majority were transient and reversible. While the sample size of this study is small, findings were aligned with the global cohort. BPd showed favorable efficacy compared with PVd, with a manageable safety profile in lenalidomide-exposed Japanese patients with RRMM.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 1

Fig. 1 Kaplan–Meier Analysis of Progression-free Survival. BPd, belantamab mafodotin, pomalidomide, and dexamethasone; PFS, progression-free survival; PVd, pomalidomide, bortezomib, and dexamethasone; NR, not reached

12-month_PFS

PFS

Fig. 1 · Panel 12-month_PFS

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel 12-month_PFS 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:off origin start曲线 2:extreme upward reversal
查看结果